What C63 covers · when clinicians use it
ICD-10 code C63 identifies Malignant neoplasm of other and unspecified male genital organs in the U.S. ICD-10-CM clinical and billing record set. It sits within the Neoplasms chapter (C00–D49), the section that groups related diagnoses so providers, payers, and public-health agencies report them consistently. Clinicians and medical coders apply C63 when an encounter's findings match the Malignant neoplasm of other and unspecified male genital organs description, attaching it to the patient record so downstream insurance claims, payer audits, quality reporting, and epidemiological surveillance all reference the same standardized diagnosis. The ICD-10-CM is maintained by the Centers for Medicare & Medicaid Services and the CDC's National Center for Health Statistics, with an updated official code set released each U.S. fiscal year — always verify C63 against the current CMS/CDC release and your payer's documentation guidance before final use. This page summarizes documentation context for C63 and is a coding reference, not clinical, diagnostic, or billing advice.
C63 refers to Malignant neoplasm of other and unspecified male genital organs, a group of cancers that affect the male reproductive system. These cancers vary in incidence, with prostate cancer being among the most common, while others like penile or testicular cancer are rarer. Proper ICD10 coding is essential for diagnosis tracking, treatment planning, and oncology reporting.
Symptoms
- Urinary changes – Weak stream, urgency, or blood in urine (common in prostate cancer)
- Scrotal swelling or lump – Notable in testicular cancer
- Pelvic pain – May indicate advanced-stage cancers
- Penile sores or growths – Warning signs of penile malignancy
- Sexual dysfunction – Including erectile or ejaculatory issues
- Fatigue or weight loss – Common in systemic disease
- Back or bone pain – May indicate metastasis
Diagnosis
Diagnosis of Malignant neoplasm of other and unspecified male genital organs involves clinical exam, blood tests (e.g., PSA for prostate cancer), imaging (ultrasound, MRI, CT), and biopsy. Early detection significantly improves prognosis, especially for testicular and prostate cancers, which often respond well to treatment when caught early.
ICD10 Code Usage
ICD10 code C63 is used in urology, oncology, and pathology settings to document male reproductive cancers. It supports cancer registry entry, insurance billing, research tracking, and continuity of care for patients with genitourinary malignancies.
Related Codes
- C60 – Malignant neoplasm of penis
- C61 – Malignant neoplasm of prostate
- C62 – Malignant neoplasm of testis
FAQs
Q1: What is ICD10 code C63?
A: This code documents Malignant neoplasm of other and unspecified male genital organs, a cancer of the male reproductive system, in clinical and billing records.
Q2: What are the risk factors?
A: Age, family history, HPV infection, lifestyle, and hormonal influences depending on cancer type.
Q3: Can these cancers be cured?
A: Many are highly treatable, especially testicular cancer and early-stage prostate cancer.
Q4: What treatments are available?
A: Surgery, hormone therapy, radiation, chemotherapy, or surveillance depending on diagnosis and stage.
Q5: Are screenings available?
A: Yes, especially for prostate cancer through PSA testing and digital rectal exams.
Conclusion
ICD10 code C63 is crucial for managing and tracking Malignant neoplasm of other and unspecified male genital organs. It helps providers offer timely interventions, informs public health strategies, and ensures proper resource allocation. Accurate coding supports better patient outcomes and long-term cancer care coordination.